SHP2
Src homology phosphatase 2; PTPN11
Src-homology-2-containing protein tyrosine phosphatase 2 (SHP2), encoded by the PTPN11 gene, is a 593 amino acid classical non-receptor protein tyrosine phosphatase (PTP). SHP2 is involved in diverse signalling pathways such as RAS-MAPK, PI3K-AKT, JAK-STAT and PD-1/PD-L1. Besides, SHP2 negatively regulates the activation of recombinant NLRP3 (NLR family, pyrin domain containing protein 3) inflammasome via mitochondrial homeostasis. SHP2 has been regarded as an extremely attractive target for human diseases therapies, particular in cancer.
All Product Categories
-
SHP2 Related Products (107)
Related Products (107)
-
Antibodies (1)
-
SHP2-IN-32
0 ImagesCat. No.: HY-169111CAS No.: 3043685-80-6SHP2-IN-32 (compound C6) is an orally active, allosteric SHP2 inhibitor with an IC50 value of 0.13 nM. SHP2-IN-32 exhibits antitumor activity.
-
SHP2/CDK4-IN-1
0 ImagesCat. No.: HY-150609CAS No.: 2924036-87-1SHP2/CDK4-IN-1 (compound 10) is an orally active and potent SHP2 and CDK4 dual inhibitor, with IC50 values of 4.3 and 18.2 nM, respectively. SHP2/CDK4-IN-1 effectively induces G0/G1 arrest to prevent the proliferation of TNBC cell lines. SHP2/CDK4-IN-1 shows significant antitumor efficacy in the EMT6 syngeneic mouse model. SHP2/CDK4-IN-1 can be used for triple-negative breast cancer (TNBC) research.
-
SHP244
0 ImagesCat. No.: HY-115527CAS No.: 902891-37-6SHP244 is a conformational inhibitor targeting the "latch allosteric site" (site 2) of the SHP2 protein with an IC50 value for SHP2WT of 60 μM. SHP244 has no significant effect on the level of p-ERK alone. SHP244 combined with RMC-4550 (HY-116009) ("tunnel site" site 1 inhibitor) can reduce p-ERK and inhibit the rebound of p-ERK, thereby reducing drug resistance. SHP244 can be used to study drug resistance in FGFR-driven cancers.
-
SHP2-IN-27
0 ImagesCat. No.: HY-162355CAS No.: 2376012-00-7SHP2-IN-27 (compound 28) is an allosteric inhibitor of tyrosine phosphatase SH2.
-
NAT6-297775
0 ImagesCat. No.: HY-180326CAS No.: 1348433-02-2NAT6-297775 (Compound 29) is a protein tyrosine phosphatase (PTP) inhibitor targeting non-receptor PTP SHP-2 with an IC50 of 2.5 μM. NAT6-297775 can inhibit the RAS/MAP kinase signaling pathway. NAT6-297775 can be used for the research of cancer, such as leukemia.
-
SHP2-IN-35
0 ImagesCat. No.: HY-170877SHP2-IN-35 (Compound 3f) is the inhibitor for SHP2. SHP2-IN-35 exhibits antiproliferative activity in cancer cells RKO, SW480 and CT26 with IC50 of 5.72 μM, 3.71 μM and 1.42 μM, respectively. SHP2-IN-35 inhibits the PI3K-Akt signaling pathway, regulates the cell cycle associated gene expressions, and induces mitochondrial-related autophagy. SHP2-IN-35 inhibits the expression of certain cytokines and chemokines in the tumor microenvironment (TME), thereby regulating the tumor progression.
-
SHP2 inhibitor LY6
0 ImagesCat. No.: HY-125257CAS No.: 2296718-09-5Synonyms: LY6SHP2 inhibitor LY6 (LY6) is a selective SHP2 inhibitor with an IC50 of 9.8 μM, showing 7-fold selectivity over SHP1. SHP2 inhibitor LY6 inhibits SHP2-mediated cell signaling pathways and suppresses cell proliferation. SHP2 inhibitor LY6 elicits induces apoptosis and G2/M cell cycle arrest in lung cancer cells. SHP2 inhibitor LY6 can be used for the research of B cell acute lymphoblastic leukemia, acute myeloid leukemia, and lung cancer.
-
SHP2-IN-5
0 ImagesSHP2-IN-5 (compound 1) is an inhibitor of SHP2 (IC50: 97 nM). SHP2 is a non-receptor protein tyrosine phosphatase associated with cell growth and proliferation. SHP2-IN-5 has the potential to inhibit cancer and SHP2-related human diseases.
-
PF-04577806
0 ImagesCat. No.: HY-139467CAS No.: 1072100-81-2
-
LXQ-217
0 ImagesCat. No.: HY-161360CAS No.: 2524718-79-2
-
CNBCA
0 ImagesCat. No.: HY-155098CAS No.: 3044817-00-4
-
SHP2-IN-44
0 ImagesCat. No.: HY-175803CAS No.: 2818955-47-2SHP2-IN-44 (Compound 26) is an allosteric and orally active SHP2 inhibitor with an IC50 of 27 ?nM. SHP2-IN-44 also inhibits ERK phosphorylation (IC50 of 299 ?nM) without off-target hERG activity. SHP2-IN-44 has a broad-spectrum anticancer activity, such as juvenile myelomonocytic leukemia, neuroblastoma and breast cancer. SHP2-IN-44 can be used for Noonan syndrome, LEOPARD syndrome and cancers research.
-
SHP2-IN-17
0 ImagesCat. No.: HY-155273CAS No.: 2941498-93-5SHP2-IN-17 (compound 192) is a SHP2 inhibitor with an IC50 value of 2 nM. SHP2-IN-17 can be used for glioblastoma research.
-
LC-SF-14
0 ImagesCat. No.: HY-172916LC-SF-14 is a selective dual inhibitor of SHP2 and FGFR (IC50 values are 71.6 and 8.9 nM, respectively). LC-SF-14 inhibits FGFR2-FRS2α-SHP2-MAPK signaling and ERK phosphorylation. LC-SF-14 inhibits the proliferation of KATOIII cancer cells (IC50: 9.2 nM). LC-SF-14 has antitumor activity in the SNU-16 xenograft mouse model. LC-SF-14 can be used in FGFR2-driven gastric cancer research.
-
SHP2-IN-36
0 ImagesCat. No.: HY-172454SHP2-IN-36 (Compound B8) is an allosteric inhibitor of SHP2, with an IC50 value of 9.0 nM. In addition, its IC50 for p-ERK is 40 nM. SHP2-IN-36 also exhibited significant antitumor activity in the KYSE520 xenograft mouse model. SHP2-IN-36 can be used for research in the field of anti-tumor .
